hifibio.com

AI-friendly mirror of hifibio.com for archive, retrieval, and machine reading.

Total Pages

210

Total Words

110,445

Cache Generated

July 26, 2026

Resources

llms.txt— AI crawler index

sitemap.xml— XML sitemap

robots.txt— crawler directives

About this Cache— methodology and usage notes

Identity

primary.md— primary company profilepublic

identity.md— cache identity profilepublic

voice.md— voice and tone guidepublic

manifest.json— manifest metadatapublic

Content Index

▸website210 pages

Homepage

▸wp-content30 pages

▸uploads30 pages

Single-Cell-Deep-Phenotyping-Nature-Biotechnology-Paper

HFB200301-AACR-2020-Poster-1

HFB200301-ASCO-2022-Poster

PowerPoint Presentation

Drug Intelligence Science (DIS�): Pioneering a high-resolution translational platform to enhance the probability of success for drug discovery and development

… 25 more pages

view all 30 pages

▸pipeline11 pages

Pipeline Overview - HiFiBio Therapeutics

▸clinical-programs4 pages

Page not found - HiFiBio Therapeutics

▸programs6 pages

HFB301001 - HiFiBio Therapeutics

HFB200301 - HiFiBio Therapeutics

HFB200603 - HiFiBio Therapeutics

HFB200604 - HiFiBio Therapeutics

HFB3024 - HiFiBio Therapeutics

… 1 more pages

view all 11 pages

▸partnering2 pages

Partnerships - HiFiBio Therapeutics

Open-Innovation Hub - HiFiBio Therapeutics

view all 2 pages

▸about7 pages

Leadership - HiFiBio Therapeutics

Scientific Founders - HiFiBio Therapeutics

Company Overview - HiFiBio Therapeutics

Board of Directors - HiFiBio Therapeutics

Scientific Advisory Board - HiFiBio Therapeutics

… 2 more pages

Join Us - HiFiBio Therapeutics

DIS Platform - HiFiBiO Therapeutics

Sample Page - HiFiBio Therapeutics

Disclaimer - HiFiBio Therapeutics

Alexandre Grassin - HiFiBio Therapeutics

Timothy Miller, MSc - HiFiBio Therapeutics

Yun-Yueh Lu, PhD - HiFiBio Therapeutics

Melissa Harney - HiFiBio Therapeutics

HiFiBiO Therapeutics Announces the Appointment of Leading I&I Experts to its Scientific Advisory Board - HiFiBio Therapeutics

Evaluation of HVEM and PD-L1 Expression Profile in Tumors as Potential Predictive Biomarkers forHFB200603, a BTLA antagonist, as Monotherapy and in Combination with Tislelizumab - HiFiBio Therapeutics

Potential Predictive Biomarkers of Clinical Benefit from Emunkitug (HFB200301) in Combination withTislelizumab: Integrated Analysis of Tumor, Peripheral Blood, and Patient Treatment History - HiFiBio Therapeutics

HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) - HiFiBio Therapeutics

Application of HiFiBiO Drug Intelligence Science (DIS®) translational platform to guide the clinical development of HFB200604, a Phase I BTLA agonist monoclonal antibody - HiFiBio Therapeutics

HFB202501, a Novel Anti-PD-1 Antibody with Enhanced Effector Functions for Precision Depletion of Pathogenic T Cells in Autoimmune Diseases - HiFiBio Therapeutics

A Novel Biparatopic KLRG1 Antibody Selectively Depletes Effector Memory CD8+ T Cells for Autoimmune Disease Treatment - HiFiBio Therapeutics

HiFiBiO Therapeutics to Present Preclinical Data of Three Leading I&I Programs at the 2025 Annual Meeting of the Federation of Clinical Immunology Societies - HiFiBio Therapeutics

CXCR5 as a Therapeutic Target in Autoimmune Diseases: Insights from Sjögren’s Disease - HiFiBio Therapeutics

HiFiBiO Therapeutics to Present Preclinical Data for A Novel Immunology Antibody at the 2025 Annual Meeting of the Clinical Immunology Society - HiFiBio Therapeutics

HiFiBiO CEO Liang Schweizer sits down with NYSE Floor Talk on how HiFiBiO is using AI to transform drug development - HiFiBio Therapeutics

Utilizing Drug Intelligence Science (DIS®) for tumor type selection and molecular characterization of HFB200603, a best-in-class B and T Lymphocyte Attenuator (BTLA) monoclonal antagonist - HiFiBio Therapeutics

Predictive and generative AI to guide the clinical development of HFB200301, a first-in-class TNFR2 agonist: Drug Intelligence Science (DIS®) - HiFiBio Therapeutics

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases - HiFiBio Therapeutics

Drug Intelligence Science (DIS®): Pioneering a high-resolution translational platform to enhance the probability of success for drug discovery and development - HiFiBio Therapeutics

HiFiBiO Therapeutics to Showcase DIS® Enabled Translational Insights from Ongoing Phase 1 Clinical Trials for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - HiFiBio Therapeutics

HiFiBiO Therapeutics to Present Phase 1 Clinical Trial Data for Two Novel Immuno-Oncology Antibodies at the 2024 Annual Congress of the European Society for Medical Oncology - HiFiBio Therapeutics

Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody, in monotherapy and in combination with the anti-PD-1 tislelizumab in patients with advanced solid tumors - HiFiBio Therapeutics

Phase I Dose Escalation Study of HFB200603, a Best-in-Class BTLA Antagonist Monoclonal Antibody in Monotherapy and in Combination with the Anti-PD-1 mAb Tislelizumab in Adult Patients with Advanced Solid Tumors - HiFiBio Therapeutics

Lynn Yang, MBA - HiFiBio Therapeutics

Cheryl Cui, PhD - HiFiBio Therapeutics

Andrew Griffiths, PhD - HiFiBio Therapeutics

Jérôme Bibette, PhD - HiFiBio Therapeutics

Robert Nicol, PhD - HiFiBio Therapeutics

David Weitz, PhD - HiFiBio Therapeutics

Bradley Bernstein, MD, PhD - HiFiBio Therapeutics

Sebastian Amigorena, PhD - HiFiBio Therapeutics

Peter Ho, MD, PhD - HiFiBio Therapeutics

Michael Croft, PhD - HiFiBio Therapeutics

Leslie Kean, MD, PhD - HiFiBio Therapeutics

Peter Taylor, MA, PhD, FRCP, FRCPE - HiFiBio Therapeutics

Marco Londei, MD - HiFiBio Therapeutics

Deepak Rao, MD, PhD - HiFiBio Therapeutics

EY Announces Liang Schweizer of HiFiBiO Therapeutics as an Entrepreneur Of The Year® 2024 New England Award Winner - HiFiBio Therapeutics

MJ Kim - HiFiBio Therapeutics

Fred Dom, MSc - HiFiBio Therapeutics

Roshan Kumar, PhD - HiFiBio Therapeutics

Jinping Gan, PhD - HiFiBio Therapeutics

Phase I Dose Escalation Trial of the First-in-Class TNFR2 Agonist Monoclonal Antibody, HFB200301, in Monotherapy and in Combination with Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in adult Patients with Advanced Solid Tumors - HiFiBio Therapeutics

A Phase I Monotherapy Dose Escalation Study of HFB301001, a Novel Next Generation OX40 agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors - HiFiBio Therapeutics

HiFiBiO Therapeutics to Present Phase 1 Clinical Trial Data for Two Novel Immuno-Oncology Agonists at the 2024 Annual Meeting of the American Society of Clinical Oncology - HiFiBio Therapeutics

Zixuan Pang, PhD - HiFiBio Therapeutics

EY Announces Liang Schweizer of HiFiBiO Therapeutics as an Entrepreneur Of The Year® 2024 New England Award Finalist - HiFiBio Therapeutics

HiFiBiO Therapeutics Receives Grant to Research Long COVID and ME/CFS in Collaboration with UMass Chan Medical School - HiFiBio Therapeutics

Optimization of T cell Co-Stimulatory Agonists: A Semi-Mechanistic PKPD Model Integrating Drug Properties and Tumor-Immune Interactions - HiFiBio Therapeutics

Integrating Public Single-Cell Transcriptomics and Patient Profiles to Guide Clinical Development - HiFiBio Therapeutics

HiFiBiO Therapeutics Presents Two Posters at the 2024 American Association for Cancer Research Annual Meeting - HiFiBio Therapeutics

HiFiBiO Therapeutics to Present at 2024 American Association for Cancer Research Annual Meeting - HiFiBio Therapeutics

Helmuth Van Es, PhD - HiFiBio Therapeutics

Fred Dom, MSc - HiFiBio Therapeutics

CEO Liang Schweizer Sits with Nasdaq to Share HiFiBiO Therapeutics’ Mission to Unlock the Curative Powers of the Immune System - HiFiBio Therapeutics

HiFiBiO Therapeutics Collaborates with Institut Gustave Roussy and France 2030 Initiative to Pioneer Personalized Immunotherapies - HiFiBio Therapeutics

HiFiBiO Therapeutics Drug Intelligence Science DIS® Platform Wins “AI Innovation of the Year” in 2023 BioTech Breakthrough Awards - HiFiBio Therapeutics

Drug Intelligence Science (DIS®) – A Cutting-Edge Translational Platform Pioneered by HiFiBiO Therapeutics – Featured in Drug Discovery Today - HiFiBio Therapeutics

Drug Intelligence Science (DIS®): Pioneering a High-Resolution Translational Platform to Enhance the Probability of Success for Drug Discovery and Development - HiFiBio Therapeutics

HiFiBiO Therapeutics Receives Approval from Chinese NMPA for IND Application for HFB200301, an Innovative Anti-Tumor Monoclonal Antibody - HiFiBio Therapeutics

Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023 - HiFiBio Therapeutics

Robert Andtbacka, MD, CM joins HiFiBiO Therapeutics as Chief Medical Officer - HiFiBio Therapeutics

HiFiBiO Therapeutics Announces First Patient First Visit for the Evaluation of HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors - HiFiBio Therapeutics

HiFiBiO Therapeutics CEO Liang Schweizer Shares Her Professional Journey and the Company’s Pioneering DIS® Approach on the Biotech2050 Podcast - HiFiBio Therapeutics

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study - HiFiBio Therapeutics

HiFiBio Therapeutics -

HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid Tumors - HiFiBio Therapeutics

Phase I Study of HFB301001, a Novel OX40 Agonist Monoclonal Antibody, in Patients with Solid Tumors Selected via Drug Intelligence Science (DIS™) - HiFiBio Therapeutics

HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB301001 at 2022 ESMO Congress - HiFiBio Therapeutics

HiFiBio Therapeutics -

Phase I Study of HFB200301, a First-in-Class TNFR2 Agonist Monoclonal Antibody in Patients with Solid Tumors Selected via Drug Intelligent Science (DIS™) - HiFiBio Therapeutics

HiFiBio Therapeutics -

Targeting Regulatory T Cells with HFB101110, a Novel Anti-Human CCR8 Antibody for the Treatment of Solid Tumors - HiFiBio Therapeutics

HiFiBio Therapeutics -

HiFiBio Therapeutics - News

HiFiBio Therapeutics -

HFB200603, a Novel Anti-BTLA Monoclonal Antibody that Provides Therapeutic Potential for Immune Escape and Synergizes with Anti-PD-1 Treatment - HiFiBio Therapeutics

Discovery of Predictive Biomarkers of Response to T Cell-Targeting Biologics Using Ex Vivo Single-Cell Profiling Coupled with TCR Clonotype Characterization - HiFiBio Therapeutics

HiFiBio Therapeutics - News

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001 - HiFiBio Therapeutics

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program - HiFiBio Therapeutics

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200301 - HiFiBio Therapeutics

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study - HiFiBio Therapeutics

HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern - HiFiBio Therapeutics

FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease - HiFiBio Therapeutics

HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS® Approach in the Clinic - HiFiBio Therapeutics

High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy Using Droplet-Based Microfluidics - HiFiBio Therapeutics

HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy - HiFiBio Therapeutics

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes - HiFiBio Therapeutics

HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody - HiFiBio Therapeutics

HFB9-2, a Novel Galectin 9 Neutralizing Antibody for the Treatment of AML and Other Cancers - HiFiBio Therapeutics

Discovery and Characterization of a Novel Anti-Human CXCR5 Antibody for the Treatment of B Cell Lymphomas - HiFiBio Therapeutics

Clinical Approach and Biomarker Strategy for HFB301001, a Novel OX40 Agonistic Antibody - HiFiBio Therapeutics

Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer - HiFiBio Therapeutics

Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody - HiFiBio Therapeutics

HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers - HiFiBio Therapeutics

Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer - HiFiBio Therapeutics

Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas - HiFiBio Therapeutics

HiFiBiO Therapeutics to Present Progress on Four Novel Immunotherapy Programs at AACR 2021 - HiFiBio Therapeutics

HiFiBiO and Gustave Roussy Researchers Demonstrate the Contribution of Galectin-9 (Gal-9) in Tumor Immune Escape - HiFiBio Therapeutics

HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by Lioness Magazine - HiFiBio Therapeutics

HiFiBiO Therapeutics CEO Liang Schweizer Interviewed by PharmaBoardRoom and Genialis Podcast - HiFiBio Therapeutics

Serial Transplantation Unmasks Galectin‐9 Contribution to Tumor Immune Escape in the MB49 Murine Model - HiFiBio Therapeutics

HiFiBiO Therapeutics CEO Liang Schweizer Named one of the World’s Top Female Founders - HiFiBio Therapeutics

HiFiBiO Therapeutics Completes First Cohort of a Phase I Study of its SARS-CoV-2 Neutralizing Antibody for the Treatment and Prevention of COVID-19 - HiFiBio Therapeutics

HiFiBiO Therapeutics CEO Liang Schweizer Receives 2020 Extraordinary Women Advancing Healthcare Award - HiFiBio Therapeutics

HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference - HiFiBio Therapeutics

HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS® Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference - HiFiBio Therapeutics

KITE AND HIFIBIO THERAPEUTICS PARTNER TO DISCOVER NOVEL TARGETS AND ANTIBODIES AGAINST ACUTE MYELOID LEUKEMIA - HiFiBio Therapeutics

HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients - HiFiBio Therapeutics

HiFiBiO Therapeutics Collaborates with Coronavirus Immunotherapy Consortium in the Fight Against COVID-19 - HiFiBio Therapeutics

HFB9-2, a Novel Galectin-9 Neutralizing Antibody to Reverse Immune Suppression in the Tumor Microenvironment - HiFiBio Therapeutics

HFB301001, a Novel OX40 agonistic Antibody with a Unique Pharmacological Profile and Innovative Biomarker Strategy - HiFiBio Therapeutics

Discovery and Characterization of Novel TNFR2 Antibodies to Modulate T Cell Activities in Immunosuppressive Environment - HiFiBio Therapeutics

HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment - HiFiBio Therapeutics

Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment - HiFiBio Therapeutics

HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy - HiFiBio Therapeutics

HiFiBiO Therapeutics Presents Three Novel Immuno-Oncology Programs at 2020 AACR Virtual Annual Meeting II - HiFiBio Therapeutics

HiFiBiO Therapeutics Unveils Several Novel Antibodies Showing Promise to Be Precision Immunotherapies for Cancer Patients - HiFiBio Therapeutics

Droplet Microfluidic Screening and Sequencing Can Vastly Expand the Universe of New Antibody Therapeutics - HiFiBio Therapeutics

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics - HiFiBio Therapeutics

High-Throughput Single-Cell Activity-Based Screening and Sequencing of Antibodies Using Droplet Microfluidics - HiFiBio Therapeutics

Biotechs Build on Single-cell Analytics for Drug R&D, as Human Cell Atlas is Mapped - HiFiBio Therapeutics

HiFiBiO Therapeutics Establishes World-Class Scientific Advisory Board - HiFiBio Therapeutics

HiFiBiO Therapeutics Closes $67 Million Series C Financing to Build on Recent Success and Advance Pipeline of Novel Antibody Drugs for Cancer and Autoimmune Disorders - HiFiBio Therapeutics

HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer - HiFiBio Therapeutics

High-Throughput Single-Cell ChIP-Seq Identifies Heterogeneity of Chromatin States in Breast Cancer - HiFiBio Therapeutics

Victa Biotherapeutics Appoints Donald W. Kufe to Board of Directors - HiFiBio Therapeutics

HiFiBiO Therapeutics and Vikas Sukhatme Join Forces to Discover and Develop Novel Antibody Treatments for Cancer - HiFiBio Therapeutics

HiFiBiO Therapeutics Acquires H-Immune Therapeutics - HiFiBio Therapeutics

Research Collaboration to Develop Technology for the Treatment of Cancer - HiFiBio Therapeutics

HiFiBiO Therapeutics Signs Multi-Target Antibody Discovery Agreement with Takeda - HiFiBio Therapeutics

HiFiBiO Therapeutics Secures $37.5 Million Series B Financing to Accelerate Pipeline of Novel Antibody Drugs to Treat Cancer and Autoimmune Disorders - HiFiBio Therapeutics

HiFiBiO and collaborators publish single-cell microfluidics work in Nature Biotechnology - HiFiBio Therapeutics

Shared Insights About Guiding Principles of Open Collaboration in Drug Discovery Today From HiFiBiO CEO Liang Schweizer - HiFiBio Therapeutics

Guiding Principles of Value creation Through Collaborative Innovation in Pharmaceutical Research - HiFiBio Therapeutics

Single-Cell Deep Phenotyping of IgG-Secreting Cells for High-Resolution Immune Monitoring - HiFiBio Therapeutics

Single-Cell Deep Phenotyping of lgG-Secreting Cells for High-Resolution Immune Monitoring - HiFiBio Therapeutics

HiFiBiO at PEPTalk - HiFiBio Therapeutics

Antibody Discovery by Deep Mining of Immune Repertoires: A Demonstration of the HiFiBiO CelliGO™ Platform Versatility and Robustness with Tetanus Toxoid Antigen as a Case Study - HiFiBio Therapeutics

HiFiBiO SAS to present advances in functional therapeutic antibody discovery at The European Antibody Congress on Tuesday, November 15, 2016 - HiFiBio Therapeutics

Antibody Discovery by Deep Mining of Immune Repertoires - HiFiBio Therapeutics

HiFiBiO SAS to Present Advances in Functional Therapeutic Antibody Discovery with Two Talks at Human Antibodies and Hybridomas Conference to Be Held in Belfast, Northern Ireland, Wednesday, November 9, 2016 - HiFiBio Therapeutics

HiFiBiO receives recognition as one of Biocentury Innovations - HiFiBio Therapeutics

HiFiBiO SAS announces participation in next generation antibody therapeutics session along with Adimab, F-Star and Innovative Targeting Solutions at BioInternational 2016 in San Francisco, USA - HiFiBio Therapeutics

HiFiBiO is Recognized as an “Innovative Start-up Company” by French President Francois Hollande at the Inauguration of the Institute Pierre-Gilles de Gennes - HiFiBio Therapeutics

HiFiBiO SAS to Report Results from the First Fully Integrated, Single-Cell Antibody Discovery Platform at IBC Antibody and Engineering Therapeutics 2015 Conference - HiFiBio Therapeutics

HiFiBiO’s next generation antibody discovery platform to be presented by Pfizer Inc. at PEGS Europe 2015 - HiFiBio Therapeutics

HiFiBiO SAS Achieves Milestone in Antibody Research Collaboration with Pfizer Inc. - HiFiBio Therapeutics

HiFiBiO to present platform at next-generation antibodies conference - HiFiBio Therapeutics

HiFiBiO partners with Johnson & Johnson Innovation - HiFiBio Therapeutics